Numerous studies on the genetic pathogenesis of familial Parkinson’s Disease (PD) have explained the etiology of only a limited percentage of cases. In this study, we aimed to identify copy number variations (CNVs) in patients with familial PD compared to their healthy siblings.
Methods
Genomic microarray analysis was performed using the CytoScan HD array platform, and paired copy number variation analysis was performed using Partek Genomics Suite.
Results
A total of 211 CNVs were detected in patients (genomic markers per CNV >10, markers per base pair >0.0005). Genes localized in CNV regions were enriched in the “Metabolism of xenobiotics by cytochrome P450” pathway. Subsequently, CNVs located in regions with segmental duplication, large genomic gap or “dosage sensitivity unlikely,” with a frequency higher than 0.01%, and found to be “both amplified and deleted” in patients were excluded. Genes potentially affected by exonic copy number losses were HPGDS, TUBB8, ZMYND11, FLI-1, THADA, FAM47E, FAM47E-STBD1, AGMO, CYRIB, and MIR5194, while the detected copy number gains included the exons of the PCSK6, MIR4522, WSB1, C8orf44-SGK3, SGK3, and MCMDC2. No copy number variations were detected on chromosomes 13 and 18.
Conclusions
Here, we report the results of the first paired CNV analysis in siblings discordant for Familial Parkinson’s Disease. Validation and frequency determination of rare and novel CNVs identified in larger familial PD cohorts may reveal novel PD risk genes. The metabolism of xenobiotics by cytochrome P450 pathway deserves further functional and translational studies in familial Parkinson’s disease.
LesageSBriceA. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet2009; 18: R48–R59. DOI: 10.1093/hmg/ddp012.
2.
HorowitzMPGreenamyreJT. Gene-environment interactions in Parkinson’s disease: the importance of animal modeling. Clin Pharmacol Ther2010; 88: 467–474. DOI: 10.1038/clpt.2010.138.
3.
KimCYAlcalayRN. Genetic forms of Parkinson’s disease. Semin Neurol2017; 37: 135–146. DOI: 10.1055/s-0037-1601567.
4.
FarrerMJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet2006; 7: 306–318. DOI: 10.1038/nrg1831.
5.
La CognataVMorelloGD’AgataV, et al.Copy number variability in Parkinson’s disease: assembling the puzzle through a systems biology approach. Hum Genet2017; 136: 13–37. DOI: 10.1007/s00439-016-1749-4.
YemniEAMoniesDAlkhairallahT, et al.Integrated analysis of whole exome sequencing and copy number evaluation in Parkinson’s disease. Sci Rep2019; 9: 3344. DOI: 10.1038/s41598-019-40102-x.
8.
FreemanJLPerryGHFeukL, et al.Copy number variation: new insights in genome diversity. Genome Res2006; 16: 949–961. DOI: 10.1101/gr.3677206.
9.
PenningsMMeijerRPPGerritsM, et al.Copy number variants from 4800 exomes contribute to ∼7% of genetic diagnoses in movement disorders, muscle disorders and neuropathies. Eur J Hum Genet2023; 31: 654–662. DOI: 10.1038/s41431-023-01312-0.
10.
SingletonABFarrerMJohnsonJ, et al.Alpha-synuclein locus triplication causes Parkinson’s disease. Science2003; 302: 841. DOI: 10.1126/science.1090278.
11.
HedrichKEskelsonCWilmotB, et al.Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord2004; 19: 1146–1157. DOI: 10.1002/mds.20234.
12.
MarongiuRBrancatiFAntoniniA, et al.Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Hum Mutat2007; 28: 98. DOI: 10.1002/humu.9472.
13.
BonifatiVRizzuPvan BarenMJ, et al.Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science2003; 299: 256–259. DOI: 10.1126/science.1077209.
14.
SeikeNYokosekiATakeuchiR, et al.Genetic variations and neuropathologic features of patients with PRKN mutations. Mov Disord2021; 36: 1634–1643. DOI: 10.1002/mds.28521.
15.
Simon-SanchezJScholzSMatarinMM, et al.Genomewide SNP assay reveals mutations underlying Parkinson disease. Hum Mutat2008; 29: 315–322. DOI: 10.1002/humu.20626.
16.
PankratzNDumitriuAHetrickKN, et al.Copy number variation in familial Parkinson disease. PLoS One2011; 6: e20988. DOI: 10.1371/journal.pone.0020988.
17.
LiuXChengRYeX, et al.Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson’s disease among ashkenazi jews. Mol Genet Genomic Med2013; 1: 142–154. DOI: 10.1002/mgg3.18.
18.
PamphlettRMorahanJMLuquinN, et al.An approach to finding brain-situated mutations in sporadic Parkinson’s disease. Parkinsonism Relat Disorders2012; 18: 82–85. DOI: 10.1016/j.parkreldis.2011.08.024.
19.
PamphlettRMorahanJMLuquinN, et al.Looking for differences in copy number between blood and brain in sporadic amyotrophic lateral sclerosis. Muscle Nerve2011; 44: 492–498. DOI: 10.1002/mus.22095.
20.
WishartAE.Somatic copy number mosaicism contributes to genomic diversity in mus musculus. Electronic Thesis and Dissertation Repository, The University of Western Ontario (Canada), 2014.
21.
MacDonaldJRZimanRYuenRK, et al.The database of genomic variants: a curated collection of structural variation in the human genome. Nucleic Acids Res2014; 42: D986–D992. DOI: 10.1093/nar/gkt958.
22.
FirthHVRichardsSMBevanAP, et al.DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. Am J Hum Genet2009; 84: 524–533. DOI: 10.1016/j.ajhg.2009.03.010.
23.
KarczewskiKJFrancioliLCTiaoG, et al.The mutational constraint spectrum quantified from variation in 141,456 humans. Nature2020; 581: 434–443. DOI: 10.1038/s41586-020-2308-7.
24.
RehmHLBergJSBrooksLD, et al.ClinGen — the clinical genome resource. N Engl J Med2015; 372: 2235–2242. DOI: 10.1056/NEJMsr1406261.
MillerDTAdamMPAradhyaS, et al.Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet2010; 86: 749–764. DOI: 10.1016/j.ajhg.2010.04.006.
27.
EstevesFRueffJKranendonkM. The central role of cytochrome P450 in xenobiotic metabolism-A brief review on a fascinating enzyme family. J Xenobiot2021; 11: 94–114. DOI: 10.3390/jox11030007.
28.
FanHHLiBQWuKY, et al.Polymorphisms of cytochromes P450 and glutathione S-transferases synergistically modulate risk for Parkinson’s disease. Front Aging Neurosci2022; 14: 888942. DOI: 10.3389/fnagi.2022.888942.
29.
HartzPFehlmannTWagenpfeilG, et al.A CYPome-wide study reveals new potential players in the pathogenesis of Parkinson’s disease. Front Pharmacol2022; 13: 1094265. DOI: 10.3389/fphar.2022.1094265.
30.
IharaKOguroAImaishiH. Diagnosis of Parkinson’s disease by investigating the inhibitory effect of serum components on P450 inhibition assay. Sci Rep2022; 12: 6622. DOI: 10.1038/s41598-022-10528-x.
31.
KakimotoAOguraHSuenagaM, et al.Role of cytochrome P450 for vitamin D metabolisms in patients with neurodegenerative disorders. Clin Park Relat Disord2022; 7: 100162. DOI: 10.1016/j.prdoa.2022.100162.
32.
Petkova-KirovaPBaasSWagenpfeilG, et al.SNPs in cytochrome P450 genes decide on the fate of individuals with genetic predisposition to Parkinson’s disease. Front Pharmacol2023; 14: 1244516. DOI: 10.3389/fphar.2023.1244516.
33.
YenerallPZhouL. Identifying the mechanisms of intron gain: progress and trends. Biol Direct2012; 7: 29. DOI: 10.1186/1745-6150-7-29.
34.
Le HirHNottAMooreMJ. How introns influence and enhance eukaryotic gene expression. Trends Biochem Sci2003; 28: 215–220. DOI: 10.1016/S0968-0004(03)00052-5.
35.
UradeYUjiharaMHoriguchiY, et al.Mast cells contain spleen-type prostaglandin D synthetase. J Biol Chem1990; 265: 371–375.
36.
UradeYUjiharaMHoriguchiY, et al.The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol1989; 143: 2982–2989.
37.
MohriIEguchiNSuzukiK, et al.Hematopoietic prostaglandin D synthase is expressed in microglia in the developing postnatal mouse brain. Glia2003; 42: 263–274. DOI: 10.1002/glia.10183.
38.
TanakaKOgawaKSugamuraK, et al.Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol2000; 164: 2277–2280.
39.
Christ-HazelhofENugterenDH. Purification and characterisation of prostaglandin endoperoxide D-isomerase, a cytoplasmic, glutathione-requiring enzyme. Biochim Biophys Acta1979; 572: 43–51.
40.
ScherJUPillingerMH. The anti-inflammatory effects of prostaglandins. J Invest Med2009; 57: 703–708. DOI: 10.2310/JIM.0b013e31819aaa76.
41.
TrivediSGNewsonJRajakariarR, et al.Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A2006; 103: 5179–5184. DOI: 10.1073/pnas.0507175103.
42.
RajakariarRHilliardMLawrenceT, et al.Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A2007; 104: 20979–20984. DOI: 10.1073/pnas.0707394104.
43.
CollinsLMToulouseAConnorTJ, et al.Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology2012; 62: 2154–2168. DOI: 10.1016/j.neuropharm.2012.01.028.
44.
JohanssonACVFeukL. Characterization of copy number-stable regions in the human genome. Hum Mutat2011; 32: 947–955. DOI: 10.1002/humu.21524.
45.
ShaabanZKhoradmehrAAmiri-YektaA, et al.Pathophysiologic mechanisms of insulin secretion and signaling-related genes in etiology of polycystic ovary syndrome. Genet Res2021; 2021: 7781823. DOI: 10.1155/2021/7781823.
46.
ParikhHLyssenkoVGroopLC. Prioritizing genes for follow-up from genome wide association studies using information on gene expression in tissues relevant for type 2 diabetes mellitus. BMC Med Genom2009; 2: 72. DOI: 10.1186/1755-8794-2-72.
47.
SimonetCBestwickJJitlalM, et al.Assessment of risk factors and early presentations of Parkinson disease in primary care in a diverse UK population. JAMA Neurol2022; 79: 359–369. DOI: 10.1001/jamaneurol.2022.0003.
48.
CoeBPWitherspoonKRosenfeldJA, et al.Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat Genet2014; 46: 1063–1071. DOI: 10.1038/ng.3092.
49.
OatesSAbsoudMGoyalS, et al.ZMYND11 variants are a novel cause of centrotemporal and generalised epilepsies with neurodevelopmental disorder. Clin Genet2021; 100: 412–429. DOI: 10.1111/cge.14023.
50.
MoskowitzAMBelnapNSiniardAL, et al.A de novo missense mutation in ZMYND11 is associated with global developmental delay, seizures, and hypotonia. Cold Spring Harb Mol Case Stud2016; 2: a000851. DOI: 10.1101/mcs.a000851.
51.
IndelicatoEZechMAmprosiM, et al.Untangling neurodevelopmental disorders in the adulthood: a movement disorder is the clue. Orphanet J Rare Dis2022; 17: 55. DOI: 10.1186/s13023-022-02218-8.
52.
WatschingerKKellerMAGoldererG, et al.Identification of the gene encoding alkylglycerol monooxygenase defines a third class of tetrahydrobiopterin-dependent enzymes. Proc Natl Acad Sci U S A2010; 107: 13672–13677. DOI: 10.1073/pnas.1002404107.
53.
SailerSKellerMAWernerER, et al.The emerging physiological role of AGMO 10 years after its gene identification. Life2021; 11: 88. DOI: 10.3390/life11020088.
54.
SarkarSDammerEBMalovicE, et al.Molecular signatures of neuroinflammation induced by αSynuclein aggregates in microglial cells. Front Immunol2020; 11: 33. DOI: 10.3389/fimmu.2020.00033.
55.
BlauwendraatCHeilbronKVallergaCL, et al.Parkinson’s disease age at onset genome-wide association study: defining heritability, genetic loci, and α-synuclein mechanisms. Mov Disord2019; 34: 866–875. DOI: 10.1002/mds.27659.
56.
ChenYYuanXCaoB, et al.No association of FAM47E rs6812193, SCARB2 rs6825004 and STX1B rs4889603 polymorphisms with Parkinson’s disease in a Chinese Han population. J Neural Transm2015; 122: 1547–1552. DOI: 10.1007/s00702-015-1430-4.
57.
NuciforaFCJrNuciforaLGNgC-H, et al.Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun2016; 7: 11792. DOI: 10.1038/ncomms11792.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
